No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients
- 25 August 2023
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (1) , E26-E28
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern ItalyActa Dermato-Venereologica, 2022
- Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infectionJournal of Dermatological Treatment, 2022
- Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi‐case report analysisClinical Case Reports, 2022
- Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort studyDermatologic Therapy, 2020
- Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm changeJournal of the European Academy of Dermatology and Venereology, 2020
- Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque PsoriasisJAMA Dermatology, 2020
- Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent TuberculosisCase Reports in Dermatology, 2019
- Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsArthritis & Rheumatism, 2005
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001